Biodesix, Inc. · NASDAQ:BDSX

Biodesix — Investor Presentation (August 2024)

24 slides from Biodesix's investor presentation, Aug 15, 2024

Slide 1: Corporate Presentation
Exhibit 99.1 Corporate Presentation Biodesix is a blood-based lung diagnostic company addressing a large unmet need with limited competition © 2024 Biodesix, Inc. All rights reserved. 1 3Q24
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ( Biodesix , “we” or the Company ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise o
Slide 3: Execution play – First mover advantage addressing estimated 5 million patients at risk of lung cancer
Execution play – First mover advantage addressing estimated 5 million patients at risk of having lung cancer • Large market: Estimated 5 million patients with lung nodules with first 42% Year mover advantage over Year Growth in • Five reimbursed tests: 5 blood-based Lung Diagnostic tests with Lung M
Slide 4: Two commercial channels driving growth
Two commercial channels driving growth Two revenue growth drivers Biopharmaceutical and Lung Diagnostic Tests Diagnostic Services Focused on early diagnosis of Biomarker discovery, assay lung cancer and personalized design and development, clinical cancer treatment with best-in- trial testing and su
Slide 5: Biodesix operates two certified, high-complexity laboratories
Biodesix operates two certified, high-complexity laboratories LOUISVILLE, CO DE SOTO, KS ü CAP-accreditedü CAP-accredited ü CLIA-certifiedü CLIA-certified ü NYS CLEP certified: Soluble Tumor ü NYS CLEP certified: Soluble Tumor Markers, Molecular & Cellular Tumor Markers & Diagnostic Immunology Marke
Slide 6: Lung cancer is the leading cause of cancer deaths, but early detection saves lives
Lung cancer is the leading cause of cancer deaths, but early detection saves lives Lung cancer deaths versus colorectal, Few patients are diagnosed early when 1 breast, and prostate combined survival is up to 10x greater 60% 150,000 50% 120,000 Prostate 40% 90,000 Breast 30% Lung 60,000 20% Colorect
Slide 7: Five blood-based Medicare covered tests for the same patient population
Five blood-based Medicare covered tests for the same patient population with best-in-class turnaround times Lung Diagnostic Testing Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Nodule Risk Assessment Treatment Guidance Testing Identify likely Identify likely Identify actionable Identi
Slide 8: Standard of care: Guideline directed lung nodule management
1 Standard of care: Guideline directed lung nodule management Assessed Risk of Lung Cancer or High Risk (>65%) Biopsy Surgery ~10% of patients Incidentally Biopsy Found Low to OR Moderate Screen Risk Physician Surgery Detected (5-65%) Judgement Lung Cancer Risk Assessment: ~80% of patients Lung Nodu
Slide 9: Standard lung cancer risk assessment has led to over- and under-treatment of patients
Standard lung cancer risk assessment has led to over- and under-treatment of patients 62% 35% 17% of patients who underwent of patients sent to CT surveillance of patients receiving biopsy 1 2 surgery had benign nodules have malignant nodules as the sole diagnostic 1 procedure were benign 1 © 2024 B
Slide 10: One blood draw, two tests to reclassify risk in lung nodule management
One blood draw, two tests to reclassify risk to help reduce uncertainty in lung nodule management Assessed Risk of Lung Cancer or High Risk (>65%) Biopsy Surgery identifies likely malignant ~10% of patients nodules with test results in one day Patient Chart Low to Clinical Profile • Age (≥40) Modera
Slide 11: Five Medicare covered tests for the same patient population
Five Medicare covered tests for the same patient population with best-in-class turnaround times Lung Diagnostic Testing Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Treatment Guidance Testing Identify likely Identify likely Identify actionable Identify actionable Identify a patient’s
Slide 12: Testing helps guide the right treatment to the right patient as quickly as possible
Testing helps guide the right treatment to the right patient as quickly as possible 26 days ~ 235k 10.5 months patients diagnosed annually median overall survival of Length of time for turnaround for 1 2 3 with NSCLC in the US patients with advanced stage NSCLC tissue testing 4 >60 treatments and co
Slide 13: Treatment guidance tests for all stages of lung cancer
Treatment guidance tests for all stages of lung cancer Early stage Advanced, metastatic, or Lung Cancer recurrent Lung Cancer Immune profiling test Immune profiling test 52-gene test Average turnaround time of 3 business days © 2024 Biodesix, Inc. All rights reserved. 13
Slide 14: Robust pipeline to address additional clinical needs for the same patient population
Robust pipeline to address additional clinical needs for the same patient population Treatment Monitoring Risk of Recurrence Minimal Residual Disease Primary Immune Response © 2024 Biodesix, Inc. All rights reserved. 14 Pipeline
Slide 15: Biopharmaceutical and Diagnostic Services partnerships
Biopharmaceutical and Diagnostic Services partnerships providing research, discovery, new test development, and clinical study testing $8.1 M in Biopharma Services under contract but not yet recognized Our Partners Our Biopharma Partnerships 60+ biopharma customers and academic partners Partnerships
Slide 16: Execution play – First mover advantage addressing estimated 5 million patients at risk of lung cancer
Execution play – First mover advantage addressing estimated 5 million patients at risk of having lung cancer • Large market: Estimated 5 million patients with lung nodules with first 42% Year mover advantage over Year Growth in • Five reimbursed tests: 5 blood-based Lung Diagnostic tests with Lung M
Slide 17: Extensive knowledge and experience in diagnostics & reimbursement
Extensive knowledge and experience in diagnostics & reimbursement Scott Hutton Robin Harper Cowie Gary Pestano Kieran O’Kane Chris Vazquez CEO CFO CDO (PhD) CCO CAO Niki Givens Mark DeBlock Steven Springmeyer James Jett Brianna Phillips VP Clin Dev VP Sales CMO (MD) CMO (MD) VP Qual & Reg © 2024 Bio
Slide 20: Blood-Based Nodule Risk Assessment
Blood-Based Nodule Risk Assessment Ordered together - Run in sequence Identifies patients with lung nodules that Identifies patients with lung nodules that are likely malignant are likely benign Proteins on an LC-MS platform from blood Autoantibodies on an ELISA platform from blood Proteins: LG3BP |
Slide 21: Rapid Turn-Around Blood-Based Tumor & Immune Profiling
Rapid Turn-Around Blood-Based Tumor & Immune Profiling Blood-based test identifies a chronic Identifies blood-based, guideline Identifies blood-based, guideline inflammatory disease state associated recommended NSCLC tumor mutations recommended tumor mutations with compromised immune system leading
Slide 22: In-Office Blood Collection with Tasso+ Capillary Device
In-Office Blood Collection with Tasso+ Capillary Device • Improves patient access to Nodify Lung® testing in practices without convenient access to venous draw services • Administered in minutes by any healthcare provider without need for Impact to Lung Nodule Patient Care venipuncture • Single-use
Slide 23: Intellectual property portfolio
Intellectual property portfolio >100 issued patents 25 unique registered and US and foreign filed trademarks across 11 countries Patent Subject Matter: Exemplary Issued Marks: Filed Marks: • VeriStrat® and Nodify® tests and their uses in non-small • Biodesix • IQlung cell lung and other diseases (e.
Slide 24: A Board of Directors with a vast amount of industry expertise
A Board of Directors with a vast amount of industry expertise John Patience Crabtree Partners LLC CHAIRMAN Scott Hutton PRESIDENT & CEO Hany Massarany CHAIR - COMPENSATION COMMITTEE Jean Franchi CHAIR - AUDIT COMMITTEE Matt Strobeck Birchview Capital CHAIR - NOMINATIONS & GOVERNANCE COMMITTEE Jack S

Biodesix — Investor Presentation (August 2024) on 6ix

Biodesix — Investor Presentation (August 2024)

Slide 1: Corporate Presentation

Slide 2: Disclaimer

Slide 3: Execution play – First mover advantage addressing estimated 5 million patients at risk of lung cancer

Slide 4: Two commercial channels driving growth

Slide 5: Biodesix operates two certified, high-complexity laboratories

Slide 6: Lung cancer is the leading cause of cancer deaths, but early detection saves lives

Slide 7: Five blood-based Medicare covered tests for the same patient population

Slide 8: Standard of care: Guideline directed lung nodule management

Slide 9: Standard lung cancer risk assessment has led to over- and under-treatment of patients

Slide 10: One blood draw, two tests to reclassify risk in lung nodule management

Slide 11: Five Medicare covered tests for the same patient population

Slide 12: Testing helps guide the right treatment to the right patient as quickly as possible

Slide 13: Treatment guidance tests for all stages of lung cancer

Slide 14: Robust pipeline to address additional clinical needs for the same patient population

Slide 15: Biopharmaceutical and Diagnostic Services partnerships

Slide 16: Execution play – First mover advantage addressing estimated 5 million patients at risk of lung cancer

Slide 17: Extensive knowledge and experience in diagnostics & reimbursement

Slide 18: Thank you!

Slide 19: Appendix

Slide 20: Blood-Based Nodule Risk Assessment

Slide 21: Rapid Turn-Around Blood-Based Tumor & Immune Profiling

Slide 22: In-Office Blood Collection with Tasso+ Capillary Device

Slide 23: Intellectual property portfolio

Slide 24: A Board of Directors with a vast amount of industry expertise